Biocon Limited – Investor Presentation Summary
Key Operational Highlights
- Biosimilars segment revenue grew 16% YoY to ₹2,855 crore, primarily driven by North America market performance
- Generics segment revenue increased 21% YoY to ₹760 crore, with generic liraglutide as a key driver across multiple markets including USA
- Services segment revenue declined 16% YoY to ₹736 crore due to lower offtake from a key biologics client and forex hedge losses
- EMA approval for second insulin drug product line in Malaysia doubles capacity and supports future growth
- Recent US commercialization includes Yesafili (bAflibercept), Bosaya & Aukelso (bDenosumab), and gLiraglutide
- Europe market saw launches of Evfraxy® (bDenosumab) and Abevmy® (bBevacizumab) across select markets
- Yesafili launched in Malaysia; continued bevacizumab leadership in Brazil
Segment-wise Performance
Biosimilars Segment:
- Q1 FY27 Revenue: ₹2,855 crore (16% YoY growth, 4% QoQ growth)
- EBITDA: ₹728 crore (10% YoY growth, 1% QoQ growth)
- EBITDA Margin: 25% (vs 27% in Q1 FY26, 26% in Q4 FY26)
- R&D Spend: ₹192 crore (7% of revenue)
Generics Segment:
- Q1 FY27 Revenue: ₹760 crore (21% YoY growth, -2% QoQ growth)
- EBITDA: ₹56 crore (vs ₹-35 crore loss in Q1 FY26, 44% QoQ growth)
- EBITDA Margin: 7% (vs -6% in Q1 FY26, 5% in Q4 FY26)
- R&D Spend: ₹47 crore (6% of revenue)
Services Segment:
- Q1 FY27 Revenue: ₹736 crore (-16% YoY, -29% QoQ)
- EBITDA: ₹116 crore (-48% YoY, -64% QoQ)
- EBITDA Margin: 15% (vs 25% in Q1 FY26, 31% in Q4 FY26)
Financial Highlights
Revenue from Operations: ₹4,336 crore (10% YoY growth)
Total Revenue: ₹4,391 crore (9% YoY growth)
R&D (Net): ₹240 crore (7% of Revenue)
EBITDA: ₹902 crore (7% YoY growth)
EBITDA Margin: 21% (vs 21% in Q1 FY26, 23% in Q4 FY26)
Profit Before Tax (Before exceptional items): ₹141 crore (24% YoY growth)
PBT Margin: 3% (vs 3% in Q1 FY26, 7% in Q4 FY26)
Net Profit (Before exceptional items): ₹145 crore (245% YoY growth)
Exceptional item, net of tax & NCI: ₹-4 crore
Net Profit (Reported): ₹141 crore
Geographical Revenue Split
North America: Largest strategic market with policy tailwinds and launch execution
Europe: Integrated portfolio of 11 biosimilars and eight generic medicines with tailored retail and tender strategies
Emerging Markets: Access-led growth through portfolio breadth and partnerships including local partnerships, CMOs and technology-transfer initiatives
Strategic & R&D Initiatives
- Strategic collaboration with BRIC-THSTI enhances translational research and clinical development capabilities
- Continued investment in Syn.AI®, digital technologies and emerging modalities
- Peptides, fermentation and manufacturing investments provide a strong platform for utilization-led margin expansion
- Regional supply network strengthened through local capabilities and strategic partnerships
- Focus on improving margins, free cash flow generation and RoCE
Management Commentary & Growth Outlook
Strategic Outlook: Growth momentum expected to build progressively through FY27, with H2 performance meaningfully better than H1. Recent launches and market access progress provide visibility on a stronger second half.
FY27 Guidance: Services segment expects FY27 to be a transition year, with performance improving in 2H. Positioned for return to sustainable growth from FY28. New management team focused on sharpening commercial execution, strengthening delivery and building more agile, cost-competitive organization.
Market Position: Integrated platform, global scale and resilient supply networks position Biocon for sustained growth. Committed to translating growth into stronger earnings and shareholder value.